Effects of Roflumilast on subclinical atherosclerosis in COPD - a randomized controlled trial
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa693
Abstract: Background: COPD is associated with an excess atherosclerotic risk. Both, COPD and atherosclerosis are mediated by systemic inflammation. Roflumilast, as an anti-inflammatory drug, revealed potential atheroprotective effects in patients with COPD. Aims: To investigate the… read more here.
Keywords: systemic inflammation; copd; effects roflumilast; roflumilast ... See more keywords